NEW YORK (GenomeWeb News) – Genomic Health's first-quarter revenues rose 17 percent year over year, the company reported after the close of the market on Wednesday.

For the three months ended March 31, total revenues increased to $58.5 million, compared to $49.8 million for Q1 2011 and exceeding consensus analyst estimates of $56.3 million.

Product revenues, which make up most of the revenues, also increased 17 percent year over year to $57.9 million from $49.5 million, while contract revenues rose 60 percent to $563,000 from $352,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.